相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Clinical implications of anti psychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders - Recent developments and current perspectives
Matthew Byerly et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2007)
Adjunctive treatment with a dopamine partial agonist, aripiprazole, for anti psychotic-induced hyperprolactinemia: A placebo-controlled trial
Joo-Cheol Shim et al.
AMERICAN JOURNAL OF PSYCHIATRY (2007)
Bone mineral density changes over a year in young females with schizophrenia: Relationship to medication and endocrine variables
A. M. Meaney et al.
SCHIZOPHRENIA RESEARCH (2007)
Psychotherapeutic medication prevalence in Medicaid-insured preschoolers
Julie M. Zito et al.
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY (2007)
Hyperprolactinemia and amenorrhea associated with olanzapine normalized after addition of aripiprazole
J. Wolf et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2007)
Treatment of schizophrenia with paliperidone extended-release tablets: A 6-week placebo-controlled trial
J. Kane et al.
SCHIZOPHRENIA RESEARCH (2007)
Risk of hip fracture in patients with a history of schizophrenia
Louise Howard et al.
BRITISH JOURNAL OF PSYCHIATRY (2007)
Adverse effects of atypical antipsychotics: Differential risk and clinical implications
Peter M. Haddad et al.
CNS DRUGS (2007)
Osteoporosis, schizophrenia and antipsychotics - The need for a comprehensive multifactorial evaluation
Uriel Halbreich
CNS DRUGS (2007)
Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia
Robert A. Rosenheck et al.
AMERICAN JOURNAL OF PSYCHIATRY (2006)
Menstrual disturbance and galactorrhea in people taking conventional antipsychotic medications
Karthik Thangavelu et al.
EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY (2006)
Atypical antipsychotics and pituitary tumors: A pharmacovigilance study
Ana Szarfman et al.
PHARMACOTHERAPY (2006)
Focus on prolactin as a metabolic hormone
N Ben-Jonathan et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2006)
Medication-induced hyperprolactinemia
ME Molitch
MAYO CLINIC PROCEEDINGS (2005)
Decreased bone mineral density in male schizophrenia patients
D Lehman et al.
SCHIZOPHRENIA RESEARCH (2005)
Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels
R Knegtering et al.
AMERICAN JOURNAL OF PSYCHIATRY (2005)
Plasma concentrations of estradiol in women suffering from schizophrenia treated with conventional versus atypical antipsychotics
N Bergemann et al.
SCHIZOPHRENIA RESEARCH (2005)
Olanzapine vs. other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study
M Lambert et al.
ACTA PSYCHIATRICA SCANDINAVICA (2005)
Osteoporosis in patients with schizophrenia
M Hummer et al.
AMERICAN JOURNAL OF PSYCHIATRY (2005)
Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*Al allele
RM Young et al.
BRITISH JOURNAL OF PSYCHIATRY (2004)
Physical health monitoring of patients with schizophrenia
SR Marder et al.
AMERICAN JOURNAL OF PSYCHIATRY (2004)
Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism
M Misra et al.
JOURNAL OF CLINICAL PSYCHIATRY (2004)
Antipsychotic-induced hyperprolactinaemia: Mechanisms, clinical features and management
PM Haddad et al.
DRUGS (2004)
Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia
AM Meaney et al.
BRITISH JOURNAL OF PSYCHIATRY (2004)
Sexuality and schizophrenia: A review
DL Kelly et al.
SCHIZOPHRENIA BULLETIN (2004)
Prolactin and the prolactin receptor: new targets of an old hormone
J Harris et al.
ANNALS OF MEDICINE (2004)
Dopamine agonist therapy or hyperprolactinemia
BJ Bankowski et al.
CLINICAL OBSTETRICS AND GYNECOLOGY (2003)
Hyperprolactinemia and bone mineral density: the potential impact of antipsychotic agents
U Naidoo et al.
PSYCHONEUROENDOCRINOLOGY (2003)
What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning?
H Knegtering et al.
PSYCHONEUROENDOCRINOLOGY (2003)
Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone
BJ Kinon et al.
PSYCHONEUROENDOCRINOLOGY (2003)
Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol:: The results of the EIRE study
J Bobes et al.
JOURNAL OF SEX & MARITAL THERAPY (2003)
Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects
U Halbreich et al.
PSYCHONEUROENDOCRINOLOGY (2003)
Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone
PJ Weiden et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2003)
Psychotropic practice patterns for youth - A 10-year perspective
JM Zito et al.
ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE (2003)
Dopamine antagonists and the development of breast cancer
PS Wang et al.
ARCHIVES OF GENERAL PSYCHIATRY (2002)
Predictors of noncompliance in patients with schizophrenia
DO Perkins
JOURNAL OF CLINICAL PSYCHIATRY (2002)
Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder
JM Kane et al.
JOURNAL OF CLINICAL PSYCHIATRY (2002)
Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone
KS Kim et al.
JOURNAL OF CLINICAL PSYCHIATRY (2002)
The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis
S Smith et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2002)
Estradiol levels in psychotic disorders
TJ Huber et al.
PSYCHONEUROENDOCRINOLOGY (2001)
Prolactin response to nemonapride, a selective antagonist for D2 like dopamine receptors, in schizophrenic patients in relation to Taq1A polymorphism of DRD2 gene
K Mihara et al.
PSYCHOPHARMACOLOGY (2000)
分享论文
